[144] Arcutis Biotherapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Arcutis Biotherapeutics filed a Form 144 disclosing a proposed sale of 41,979 shares of common stock to be executed through Merrill with an aggregate market value of $611,936. The filing lists the approximate sale date as 08/08/2025 and records total shares outstanding of 119,201,724. The securities were acquired from Arcutis by stock option exercise on 04/10/2024 and are described as shares to be delivered on the stated sale date.

The filing also shows a recent sale in the prior three months: 53,187 shares sold on 08/06/2025 for gross proceeds of $797,466 (seller named as David Topper). The notice includes the standard attestation that the person for whose account the shares will be sold does not possess undisclosed material adverse information about the issuer.

Positive

• Complete transaction detail: the filing specifies the number of shares (41,979), aggregate market value ($611,936), and approximate sale date (08/08/2025)
• Acquisition origin disclosed: the securities were acquired by stock option exercise on 04/10/2024, clarifying basis of ownership
• Attestation included: filer represents they do not possess undisclosed material adverse information, consistent with Form 144 requirements

Negative

• Filer identification fields incomplete: visible sections for filer CIK/CCC and submission contact appear blank in the provided content
• Relationship to issuer not specified: the filing text does not clearly state the filer’s relationship to the issuer in the displayed fields

Insights

Financial Analyst

TL;DR: Insider plans to sell 41,979 ARQT shares (value $611,936); recent prior sale of 53,187 shares for $797,466—routine liquidity, limited disclosed impact.

The Form 144 documents a proposed insider sale of common stock acquired via a stock option exercise on 04/10/2024. The proposed transaction is modest in dollar terms relative to typical market caps for publicly traded biotechs, and the filing records the broker (Merrill) and an approximate sale date of 08/08/2025. A recent sale of 53,187 shares on 08/06/2025 for $797,466 is also disclosed. Based solely on the filing, this appears to be a routine disclosure of insider liquidity rather than company operational news.

Compliance/Risk Analyst

TL;DR: Form 144 filed with required attestation; document notes broker details and past sales, indicating procedural compliance with insider sale rules.

The filing includes explicit data required under Rule 144: class of securities, number of shares (41,979), aggregate market value ($611,936), acquisition method (stock option exercise on 04/10/2024), broker name and address (Merrill, Columbus, OH), and an approximate sale date (08/08/2025). It also lists a prior sale by David Topper of 53,187 shares on 08/06/2025. The notice contains the standard representation that the seller does not possess undisclosed material adverse information, which is a required attestation for such filings.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill 8890 Lyra Dr. 5th Floor Columbus OH 43240	41979	611936.00	119201724	08/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/10/2024	Stock Option Exercise	Arcutis Biotherapeutics, Inc.			41979	08/08/2025	Shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Topper 3027 TOWNSGATE ROAD SUITE 300 WESTLAKE VILLAGE CA 91361	Common	08/06/2025	53187	797466.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ARQT Form 144 disclose?

The filing discloses a proposed sale of 41,979 Arcutis (ARQT) common shares valued at $611,936, to be sold via Merrill on 08/08/2025.

How were the shares being sold acquired?

The securities to be sold were acquired by stock option exercise on 04/10/2024, per the filing.

Were there any recent sales in the past three months?

Yes. The filing shows 53,187 shares sold on 08/06/2025 for gross proceeds of $797,466, seller listed as David Topper.

How many Arcutis shares are outstanding according to the filing?

The filing reports 119,201,724 shares outstanding.

Does the Form 144 include a representation about material nonpublic information?

Yes. The person for whose account the securities are to be sold represents they do not know any material adverse information about the issuer that has not been publicly disclosed.